Compare Goldman Sachs Physical Gold ETF (AAAU) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs Illumina, Inc. — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.47, while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: Illumina, Inc. is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.
| AAAU | ILMN | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $205.10 |
52-Week Low | $32.74 | $91.00 |
Market Cap | — | $28.96B |
Enterprise Value | — | $30.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused asset, trades at $42.81, up 2.22% in the past 24 hours. Technical indicators show a bullish overall signal with strong moving average support, though oscillators suggest caution due to overbought RSI levels. Recent news highlights gold's rebound potential, with analysts citing supportive factors like central bank buying and easing Fed expectations as catalysts for further price appreciation.
The outlook for AAAU remains positive, driven by gold's strategic role amid geopolitical and fiscal uncertainties. Key risks include potential Fed policy shifts and market volatility, but institutional accumulation and bullish analyst forecasts indicate sustained investor confidence in gold's upward trajectory.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
